Product Name: RIPK1 (381-387) pY384
Product Number: PE-04APH99
Size: 200 µg      Price:47.00
1 mg      $US94.00
5 mg      206.00
Peptide Name: RIPK1 (381-387) pY384

Product Use: Services as a blocking peptide for use with the RIPK1-pY384 rabbit polyclonal antibody (Cat. No.: AB-PK795) that is also available from Kinexus. This phosphopeptide may also be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the region between the kinase catalytic and RHIM domains. This is a major in vivo phosphorylation site in RIPK1. The effect of its phosphorylation is unclear.

Peptide Production Method: Solid-phase peptide synthesis

Peptide Origin: Homo sapiens

Peptide Sequence: EAN-pY-HLY

Peptide Modifications N Terminus: Free amino

Peptide Modifications C Terminus: βAla-Cys
Peptide Modifications Other: Phosphorylated

Peptide Molecular Mass Calculated: 1162.15 Da

Peptide Purity Percent after Synthesis and Purification: >95

Peptide Appearance: White powder

Peptide Form: Solid

Storage Conditions: -20°C

Related Product 1: RIPK1 - pY384 phosphosite-specific antibody (Cat. No.: AB-PK795)

Scientific Background: RIPK1 (RIP) is a protein-serine/threonine kinase of the TKL group and RIPK family. It has a role in inducing inflammation and necroptosis (programmed necrosis). RIPK1 has also been noted to function in the initial TLR3 recognition of dsRNA in a viral infection. A S161A mutation has been noted to decrease kinase phosphotransferase activity of RIPK1. A S161E mutation has no effect on autophosphorylation of RIPK1. Caspase-8-mediated RIPK1 cleavage is impaired through a D324K mutation. NF-kB induction through RIPK1 can be inhibited via a K377R mutation. The phosphotransferase activity of RIPK1 and its NF-kB activation are, surprisingly, not essential for the anti-apoptotic function of this protein in epithelial tissues.